SecBot SecBot
SECBOTREPLAY Home › Report › DRTSW

DRTSW · Alpha Tau announced positive overall survival results from pooled Phase…

Alpha Tau Medical Ltd. · 6-K filed Jun 1, 2026 at 09:00 ET

At the news

BULLISHIMPACT 7/10

6-K filed Jun 1, 2026 at 09:00 ET

Alpha Tau announced positive overall survival results from pooled Phase I/II Alpha DaRT pancreatic cancer studies at ASCO 2026. Median OS for second-line metastatic patients was 11.2 months vs historical ~4-6 months, with a favorable safety profile (no treatment-related deaths). The data de-risks the platform and supports advancement of the IMPACT trial.

  • Pooled analysis of three Phase I/II studies in locally advanced or metastatic PDAC.
  • Second-line metastatic mOS: 11.2 months from enrollment (historical ~4-6 months).
  • Second-line locally advanced mOS: 11.1 months from enrollment (historical ~9 months).
  • Third-line metastatic mOS: 7.9 months from enrollment (historical ~4-7 months).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access